Cancer Family
Female Reproductive System Adnexal Neoplasm
CI-CAN-00000180Explore in graph →
Non-malignant764 active trials5 approved drugs94 evidence items
- NCIt
- C212117
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000180Explore in graph →
Clinical trials
3,475 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02432378 | Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04149145 | Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer(PARP) | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Jun 5, 2026 |
| clinicaltrials |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT07060365 | A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | AstraZenecaINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Thera SolutionsINDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) | withdrawn | Phase 1 / Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | withdrawn | Phase 1 | 0 | Haider MahdiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT02117817 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | withdrawn | Phase 1 | 0 | Rutgers, The State University of New JerseyOTHER | 0 | Jul 28, 2022 | clinicaltrials |
| NCT04941378 | OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT04611139 | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | withdrawn | Phase 1 | 0 | HonorHealth Research InstituteOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03400306 | A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer | withdrawn | Phase 1 | 0 | AbbVieINDUSTRY | 0 | Dec 8, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03644459 | Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 | withdrawn | Phase 1 | 0 | Lynkcell Inc.OTHER | 0 | Mar 11, 2020 | clinicaltrials |
| NCT03281681 | A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer(REPROVe) | withdrawn | Phase 1 / Phase 2 | 0 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02050009 | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02833506 | Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 1, 2018 | clinicaltrials |
| NCT00562185 | Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01386502 | CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00603460 | DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of PennsylvaniaOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 24, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT00842582 | Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer | withdrawn | Phase 1 | 0 | Loyola UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT02470559 | Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | withdrawn | Phase 1 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Feb 17, 2016 | clinicaltrials |
| NCT01624493 | BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | Hoosier Cancer Research NetworkOTHER | 3 | Dec 23, 2015 | clinicaltrials |
| NCT01880996 | Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Sheba Medical CenterOTHER_GOV | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression | withdrawn | Phase 1 | 0 | NYU Langone HealthOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Dec 18, 2013 | clinicaltrials |
| NCT00017537 | Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Aug 5, 2013 | clinicaltrials |
| NCT00942838 | Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity(WAR) | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT00118300 | Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 8, 2011 | clinicaltrials |
| NCT01000896 | Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | withdrawn | Phase 1 | 27 | AstraZenecaINDUSTRY | 1 | Feb 4, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2026source: clinicaltrials